Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) has held its inaugural Scientific Advisory Board (SAB) meeting in London, hosted by Dr Valentino Parravicini, OCTP's chief scientific officer.
Topics for discussion focussed on linking pre-clinical research, clinical trials and the care of patients.
The SAB also provided advice and guidance on the design of the company's upcoming Phase 1 clinical trials for OCT130401 and OCT461201, anticipated in Q4 2022 and Q1 2023 respectively, to help OCTP best address the needs of patients.
Parravicini was joined by Professor Anthony Dickenson (University College London), Dr Giorgio Lambru (Guy's and St Thomas' NHS Foundation Trust, London), and Professor Robert Dworkin (Rochester Medica Center School of Medicine and Dentistry, New York).
Parravicini said: "It is a great privilege to benefit from the vast experience of Professors Dworkin and Dickenson and Dr Lambru. The meeting was very engaging, generating new, innovative proposals to strengthen the group's clinical strategy which I am looking forward to putting into action."